DelMar Pharmaceuticals (NASDAQ:DMPI) Sees Strong Trading Volume

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) saw unusually-strong trading volume on Thursday . Approximately 1,803,477 shares were traded during mid-day trading, an increase of 1,100% from the previous session’s volume of 150,273 shares.The stock last traded at $1.28 and had previously closed at $1.19.

Separately, ValuEngine raised DelMar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th.

The firm’s fifty day moving average price is $2.03.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.67) earnings per share for the quarter.

An institutional investor recently raised its position in DelMar Pharmaceuticals stock. Virtu Financial LLC lifted its position in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) by 99.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,554 shares of the company’s stock after buying an additional 49,200 shares during the period. Virtu Financial LLC owned about 0.39% of DelMar Pharmaceuticals worth $48,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.85% of the company’s stock.

DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.

Featured Story: How to Use the New Google Finance Tool

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.